2,2-Dimethyl-4-heptanol | 66793-99-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2-Dimethyl-4-heptanol
• 英文别名: 2,2-dimethyl-heptan-4-ol；Propyl-neopentyl-carbinol；2,2-Dimethylheptan-4-ol
• CAS: 66793-99-5
• 化学式: C₉H₂₀O
• 分子量: 144.257
• InChiKey: ZIKNXBYJTDTRQA-UHFFFAOYSA-N

物化性质

• 沸点：
  85 °C(Press: 29 Torr)
• 密度：
  0.824±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,2-Dimethyl-4-heptanol 在 降冰片烯 、 (1,5-cyclooctadiene)(methoxy)iridium(I) dimer 、 2,3,4,6,7,9,10,11-octahydropyrazino[1,2-a:4,3-a']bipyrimidine 作用下， 以 四氢呋喃 为溶剂， 反应 18.5h， 生成
  参考文献：
  名称：

  铱催化的仲醇和酮中仲 C（sp3）–H 键的位点选择性硅烷化

  摘要：

  我们报道了铱催化的立体选择性转化，通过次级 C-H 键与氧γ硅烷化和所得恶氮环的氧化，仲醇或酮体向抗 1,3-二醇的立体选择性转化。醇或酮衍生的仲甲硅烷基醚中次级 C-H 键的硅烷基化是通过由简单的比沙脒配体形成的催化剂实现的。硅烷基化在与氧γ的次级 C-H 键处以高选择性发生，超过远端初级或近端次级 C-H 键。初步机理研究表明，新实现的反应性来源是强电子供体比沙脒配体的高结合常数导致的较长催化剂寿命。

  DOI：

  10.1021/jacs.3c03127
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醚 、 sodium 作用下， 生成 2,2-Dimethyl-4-heptanol
  参考文献：
  名称：

  Ansell et al., Chemistry and industry, 1955, p. 1483

  摘要：

  DOI：

文献信息

• PROCESS FOR PRODUCING ESTER COMPOUND
  申请人：Imazeki Shigeaki

  公开号：US20100324314A1

  公开（公告）日：2010-12-23

  PROBLEM To provide an environmentally-friendly method for producing industrially an ester compound. SOLUTION The present invention is a method for producing an ester compound which comprises subjecting a carboxylic acid and an alcohol to dehydration-condensation reaction using an involatile acid catalyst and then removing the residual acid catalyst by bringing a weak basic substance into contact with the residual acid catalyst.

  问题提供一种生产工业酯化合物的环保方法。 解决方案是一种生产酯化合物的方法，包括将羧酸和醇经过脱水缩合反应，使用一种不挥发的酸催化剂，然后通过将弱碱性物质与残留的酸催化剂接触来去除残留的酸催化剂。
• AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS
  申请人：BIGNAN Gilles

  公开号：US20110200586A1

  公开（公告）日：2011-08-18

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式（I）的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，并用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿性关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），骨相关疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的癌症），心血管疾病，软骨相关疾病（如软骨损伤/丧失，软骨退化，以及与软骨形成有关的疾病），软骨发育不良，软骨肉瘤，慢性背部受伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺疾病，糖尿病，能量稳态失调疾病，痛风，假性痛风，脂质代谢紊乱，代谢综合征，多发性骨髓瘤，肥胖，骨关节炎，进行性骨折性骨转移，软骨软化症，骨质疏松症，帕吉特病，牙周疾病，多肌痛风，Reiter综合征，重复性应力损伤，高血糖，血糖水平升高和胰岛素抵抗等症状的方法。
• MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20140057906A1

  公开（公告）日：2014-02-27

  Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物，可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节因子（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• CONDUCTIVE INK, CONDUCTIVE CIRCUIT AND NON-CONTACT MEDIA
  申请人：Toyo Ink Manufacturing CO., LTD.

  公开号：EP2078738A1

  公开（公告）日：2009-07-15

  Disclosed is an active energy ray-curable conductive ink containing a conductive substance and a binder component, which is characterized in that the binder component contains a chlorinated polyester and an active energy ray-polymerizable compound. This active energy ray-curable conductive ink has good fluidity and enables to obtain a conductive circuit with low resistance after curing. Also disclosed are a method for forming a conductive circuit by printing this conductive ink on a substrate, and non-contact media comprising an IC chip mounted in a state electrically connected with the conductive circuit. The conductive substance is preferably a flake powder having a BET specific surface area of 0.1 - 0.4 m2/g and an aspect ratio of not less than 3.

  本发明公开了一种含有导电物质和粘合剂成分的活性能量射线固化导电油墨，其特征在于粘合剂成分含有氯化聚酯和活性能量射线可聚合化合物。这种活性能量射线固化导电油墨具有良好的流动性，固化后可获得低电阻的导电电路。此外，还公开了一种通过在基板上印刷这种导电油墨来形成导电电路的方法，以及包括集成电路芯片的非接触式介质，该芯片安装在与导电电路电连接的状态下。导电物质最好是片状粉末，其 BET 比表面积为 0.1 - 0.4 m2/g，长宽比不小于 3。
• The Action of Primary Grignard Reagents on t-Butylacetyl Chloride
  作者：Frank C. Whitmore、A. H. Popkin、J. S. Whitaker、K. F. Mattil、J. D. Zech

  DOI：10.1021/ja01277a048

  日期：1938.10